Concepedia
Statistics
Publications
35
Citations
1.4K
H-Index
23
Active since
1991
Affiliations
Amgen (United States)(Current)
Washington State University
Pfizer (United States)
Arqule (United States)
University of Minnesota
Jan L. Wahlstrom is an author at Amgen (United States) specializing in pharmacology, cytochrome p450 enzymes, and medicine.
Publications per year
1991–2025
CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles
Vikas Kumar, Jan L. Wahlstrom, Dan A. Rock et al. · Drug Metabolism and Disposition · 2006 · 132 citations
Medicine, Pharmacokinetics, Pharmacology +16
Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation
R. Foti, Dan A. Rock, Larry C. Wienkers et al. · Drug Metabolism and Disposition · 2010 · 130 citations
Medicine, Pharmacokinetics, Pharmacology +17
Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition
Brooke M. VandenBrink, R. Foti, Dan A. Rock et al. · Drug Metabolism and Disposition · 2011 · 79 citations
Detritylation of Ethers Using Iodine−Alcohol Reagents: An Acid-Catalyzed Reaction
Jan L. Wahlstrom, Robert C. Ronald · The Journal of Organic Chemistry · 1998 · 76 citations
Natural Sciences, Chemistry, Analytical Chemistry +7
Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate
Brooke M. VandenBrink, R. Foti, Dan A. Rock et al. · Drug Metabolism and Disposition · 2011 · 72 citations
Medicine, Pharmacokinetics, Pharmacology +15
1–5 of 35